Introduction
============

Polycyclic tetramate macrolactams (PTMs) feature a tetramate-embedding macrocyclic lactam ring that is fused to a subset of diverse carbocyclic ring systems ([Fig. 1](#fig1){ref-type="fig"}),^[@cit1]^ such as the 5/5 ring system in alteramides (**1**, **2**),^[@cit2]^ 5/5/6 ring system in HSAF (heat-stable antifungal factor, **3**), lysobacteramide B (**4**),^[@cit3],[@cit4]^ and frontalamides (**5**, **6**),^[@cit5]^ 5/6/5 ring system in ikarugamycin (**7**)^[@cit6]^ and butremycin (**8**),^[@cit7]^ and 5/4/6 ring system in **9**.^[@cit8]^ PTMs exhibit a wide range of antifungal, antibacterial, antiprotozoal, antiulcer, antiviral, cytotoxic, and apoptosis-inducing biological activities.^[@cit1]^ As such, PTMs have shown significant potential in both agricultural and medicinal applications.^[@cit1]^

![Representative PTMs (**1--9**) and the key precursor (**10**).](c6sc03875a-f1){#fig1}

The structural complexity of PTMs has greatly hampered efforts towards their total synthesis.^[@cit9]--[@cit12]^ In sharp contrast, nature has developed a conserved and compact biosynthetic pathway to construct the complex structures of PTMs.^[@cit1],[@cit13]^ PTMs were revealed to have originated from a conserved hybrid polyketide synthase (PKS)/non-ribosomal peptide synthetase (NRPS) pathway.^[@cit5]^ The PKS was iteratively used to generate two separate polyketide chains that were respectively condensed to the α- and δ-amino groups of an [l]{.smallcaps}-ornithine tethered in the NRPS, leading to a common tetramate-containing polyene precursor **10** ([Fig. 1](#fig1){ref-type="fig"}).^[@cit8],[@cit14]--[@cit17]^ The extraordinary simplicity of PTM biosynthesis was exemplified by a three-gene cassette (*ikaABC*) mediated production of ikarugamycin (**7**) in a heterologous host.^[@cit15],[@cit16]^ However, the enzymatic machinery that dictates the manner of the divergent cyclization cascades that convert **10** into diverse ring systems in PTMs remains mysterious.^[@cit1]^ The only well studied example was the formation of the inner five-membered ring in **7**, which is catalyzed by the alcohol dehydrogenase IkaC in the manner of a Michael addition reaction.^[@cit15]^

A genomic survey has revealed the wide distribution of conserved PTM biosynthetic gene clusters in phylogenetically diverse bacteria.^[@cit5]^ However, most of them are silent.^[@cit1],[@cit5]^ Recently, different strategies were employed to successfully activate silent PTM gene clusters for the production of new PTMs, including promoter engineering^[@cit18]^ and the heterologous expression of a reconstituted PTM gene cluster *via* synthetic biology.^[@cit8]^ The success of these strategies highlights the potential for the discovery of new PTMs by the genome mining-based activation of PTM gene clusters. Herein we report (i) the activation of a cryptic PTM biosynthetic gene cluster in the marine-derived *Streptomyces pactum* SCSIO 02999 *via* promoter engineering; (ii) the isolation, characterization and cytotoxicity determination of six new PTMs, the pactamides A--F; (iii) the discovery of a reductive cyclization cascade to sequentially generate the 5, 5/5 and 5/5/6 ring systems in pactamides by the inactivation of three oxidoreductase-encoding genes (*ptmB2*, *ptmB1* and *ptmC*) and analysis of the corresponding intermediates; (iv) the biochemical demonstration of the alcohol dehydrogenase PtmC as a bifunctional cyclase capable of mediating the formation of both six- and five-membered inner rings in PTMs.

Results and discussion
======================

Identification of a putative PTM gene cluster by genome mining
--------------------------------------------------------------

Deep-sea derived *S. pactum* SCSIO 02999 has been shown to produce xiamycin-related indolosesquiterpenes as major products, and the xiamycin biosynthetic gene cluster (*xia*) was identified by genome sequencing.^[@cit19]--[@cit22]^ Further genomic analysis reveals the presence of a 14.8 kb biosynthetic gene cluster (GenBank accession number KU569222) composed of five genes (*ptmD*, *ptmA*, *ptmB1*, *ptmB2*, and *ptmC*) that are highly homologous to the PTM biosynthetic genes, immediately neighbouring the *xia* gene cluster ([Fig. 2A](#fig2){ref-type="fig"}, Table S1[†](#fn1){ref-type="fn"}). The PtmD protein has over 50% identity with those hydroxylases (previously annotated as sterol desaturases^[@cit3]^) which were established as introducing the hydroxy group at the ornithine moiety of PTMs.^[@cit5],[@cit23],[@cit24]^ PtmA is predicted to be a typical hybrid PKS/NRPS protein, and shows a high similarity to PTM PKS/NRPS proteins such as IkaA,^[@cit15],[@cit16]^ FtdB,^[@cit5]^ and HSAF PKS/NRPS.^[@cit3]^ PtmB1 is highly homologous to FAD-dependent oxidoreductases in other PTM pathways, while PtmB2 is highly similar to a number of phytoene dehydrogenases putatively involved in PTM biosynthesis (Table S1[†](#fn1){ref-type="fn"}).^[@cit1]^ PtmC bears a striking resemblance to alcohol dehydrogenases involved in PTM biosynthesis, such as FtdE,^[@cit5]^ OX4,^[@cit14]^ and IkaC.^[@cit15]^

![(A) (A) Genetic organization of the *ptm* gene cluster in pCSG2404 from a genomic library of *S. pactum* SCSIO 02999. (B) HPLC analysis of metabolite profile of different strains: (i) *S. pactum* 2999XM47i, where *xiaP* is in-frame deleted; (ii) *S. lividans* TK64/pCSG2801, no promoter inserted; (iii) *S. lividans* TK64/pSET152; (iv) *S. lividans* TK64/pCSG2804, where *ermE*\*p is inserted in front of *ptmA*; (v) *S. lividans* TK64/pCSG2805, where *ermE*\*p is inserted in front of *ptmD*; (vi) *S. lividans* TK64/pCSG2809, where *ermE*\*p is inserted in front of *ptmA* and *ptmC* is in-frame deleted; (vii) *S. lividans* TK64/pCSG2811, where *ermE*\*p is inserted in front of *ptmA* and *ptmB1* is in-frame deleted; (viii) S. *lividans* TK64/pCSG2814, where *ermE*\*p is inserted in front of *ptmA* and *ptmB2* is in-frame deleted; (ix) *S. pactum* 02999PTMp1, where *ermE*\*p is inserted in front of *ptmA*. (i)--(vii) and (ix), detection at 300 nm; (viii), detection at 360 nm. The "\#" symbols denote uncharacterized PTM-like products. (C) Chemical structures of patamides A--F (**11--16**).](c6sc03875a-f2){#fig2}

Activation and characterization of the cryptic PTM gene cluster
---------------------------------------------------------------

The presence of a conserved PTM biosynthetic gene cluster in *S. pactum* SCSIO 02999 suggests its potential for PTM production. However, no PTM-like compounds were detected either in the wild type *S. pactum* SCSIO 02999 (data not shown), or in the mutant 2999XM47i (Table S2[†](#fn1){ref-type="fn"}) where the *xiaP* gene (encoding an essential polyprenyl synthetase for xiamycin biosynthesis^[@cit19]^) was in-frame deleted to abolish the production of xiamycin-type indolosesquiterpenes and hence facilitate the detection of secondary metabolites other than xiamycins ([Fig. 2B](#fig2){ref-type="fig"}, trace i). The cosmid pCSG2404 (Table S2[†](#fn1){ref-type="fn"}), obtained in our previous work in screening the xiamycin gene cluster,^[@cit19]^ was found to contain the intact PTM gene cluster. However, introduction of the cosmid pCSG2801 (Table S2[†](#fn1){ref-type="fn"}), a derivative of pCSG2404 in which the *neo* gene (encoding kanamycin resistance) was replaced by a gene cassette containing *aac(3)IV* (encoding apramycin resistance), *oriT* (for conjugation), and *Int*φ*C31* (for specific integration into *Streptomyces* species) from pSET152A′B^[@cit25]^ (Table S2[†](#fn1){ref-type="fn"}) into *Streptomyces lividans* TK64, resulted in no observed production of PTM-like compounds ([Fig. 2B](#fig2){ref-type="fig"}, trace ii), similar to the control strain *S. lividans* TK64/pSET152 ([Fig. 2B](#fig2){ref-type="fig"}, trace iii).

In attempts to activate the PTM gene cluster, the constitutive promoter *ermE*\*p from pPWW50,^[@cit26]^ was inserted independently in front of *ptmA* and *ptmD* for heterologous expression in *S. lividans* TK64 (Tables S2 and S3; Fig. S1 and S2[†](#fn1){ref-type="fn"}). Interestingly, a number of products with UV spectra similar to PTMs, such as **11--15** ([Fig. 2B](#fig2){ref-type="fig"}, trace iv), were detected when the *ermE*\*p promoter was inserted in front of *ptmA*. Surprisingly, no PTMs were observed upon inserting the *ermE*\*p promoter in front of *ptmD* ([Fig. 2B](#fig2){ref-type="fig"}, trace v). For in-frame gene deletion experiments, we subsequently constructed three cosmids, pCSG2809 (Δ*ptmC*), pCSG2811 (Δ*ptmB1*), and pCSG2814 (Δ*ptmB2*), in which the *ermE*\*p promoter was inserted in front of *ptmA* (Fig. S3--S5[†](#fn1){ref-type="fn"}). Compound **13** was found to be the major product upon inactivating *ptmC* ([Fig. 2B](#fig2){ref-type="fig"}, trace vi), whereas **15** became the major product when *ptmB1* was inactivated ([Fig. 2B](#fig2){ref-type="fig"}, trace vii). When ptmB2 was in-frame deleted, compound **10** was the major product ([Fig. 2B](#fig2){ref-type="fig"}, trace viii). The identity of compound **10** ([Fig. 1](#fig1){ref-type="fig"}) was deduced from its UV spectrum and mass (*m*/*z* 475.4 \[M + H\]^+^, 473.6 \[M -- H\]^--^) which were almost identical to those of **10** from the Δ*ikaB* mutant in the biosynthesis of **7** (Fig. S6[†](#fn1){ref-type="fn"}).^[@cit15]^

Finally, an attempt was made to *in situ* activate the *ptm*-gene cluster in *S. pactum* 2999XM47i to afford a corresponding mutant 2999PTMp1 (Table S2[†](#fn1){ref-type="fn"}), in which the *ermE*\*p promoter was inserted in front of *ptmA*. The fermentation of 2999PTMp1 also led to the production of a number of PTMs, including **10--16** ([Fig. 2B](#fig2){ref-type="fig"}, trace ix).

Isolation, structure elucidation and cytotoxicity determination of new PTMs
---------------------------------------------------------------------------

Pactamides A--F (**11--16**, [Fig. 2C](#fig2){ref-type="fig"}) were isolated from the fermentation extracts of *S. pactum* 2999PTMp1, *S. lividans* TK64/pCSG2809, or *S. lividans* TK64/pCSG2811 (ESI[†](#fn1){ref-type="fn"}), and their structures were elucidated by extensive interpretation of the spectroscopic/spectrometric data (Tables S4--S7, Fig. S7--S13[†](#fn1){ref-type="fn"}) including high resolution electrospray ionization mass spectrometry (HRESIMS), 1D and 2D NMR, and electronic circular dichroism spectroscopy (ECD). The molecular formula of pactamide A (**11**) was established as C~29~H~40~N~2~O~4~ by HRESIMS. The planar structure of **11** was elucidated by comparing the NMR spectroscopic data of **11** (Tables S4 and S5, Fig. S7[†](#fn1){ref-type="fn"}) and **4** ([Fig. 1](#fig1){ref-type="fig"}).^[@cit4]^ The relative configuration of **11** was deduced by the proton coupling constants (*Z*Δ^2,3^ *J* ~2,3~ 11.5 Hz; *E*Δ^17,18^ *J* ~17,18~ 15.0 Hz, Table S4[†](#fn1){ref-type="fn"}) and NOESY correlations (Fig. S7[†](#fn1){ref-type="fn"}). The assignment of H-5/H-11/H-13 on the same side of the 5/5/6-tricyclic ring system in **11**, and H-6/H-8/H-10/H-12/H-16/H~3~-31 on another side, was supported by the observed NOESY correlations (Fig. S7[†](#fn1){ref-type="fn"}). On the basis of the biosynthetic origin of the [l]{.smallcaps}-ornithine of PTMs,^[@cit1],[@cit4]^ the *S*-configuration was assignable to C-23. Given that **11** and **4** exhibited almost identical ECD spectra (Fig. S8[†](#fn1){ref-type="fn"}),^[@cit4]^ the absolute configuration of **11** was deduced as 5*R*, 6*S*, 8*S*, 10*S*, 11*R*, 12*R*, 13*S*, 16*R* and 23*S*. Similarly, the structures of pactamides B--F (**12--16**) were determined (see the ESI[†](#fn1){ref-type="fn"} for the structure elucidation). The *trans*-orientation of H-10/H-11 in **11**, **13** and **15** is similar to that in aburatubolactam A.^[@cit27]^ In contrast, a *cis*-orientation of H-10/H-11 was found in other PTMs with determined relative configurations ([Fig. 1](#fig1){ref-type="fig"} and S14[†](#fn1){ref-type="fn"}).^[@cit1]^ Pactamide D (**14**) contains a Δ^9,10^ double bond, similar to that in the marine sponge metabolites cylindramide^[@cit28]^ and geodin A^[@cit29]^ (Fig. S14[†](#fn1){ref-type="fn"}), whereas **12** contains a unique Δ^10,11^ double bond. Pactamide F (**16**) represents the first example of a halogenated PTM. Pactamides A--F (**11--16**) exhibited *in vitro* antiproliferative activity against four cancer cell lines (SF-268, MCF-7, NCI-H460 and Hep-G2) with IC~50~ values ranging from 0.24--26 μM ([Table 1](#tab1){ref-type="table"}). Pactamide A (**11**) displayed the best cytotoxic activity with IC~50~ values of 0.24--0.51 μM, and these were better than those of lysobacteramides and HSAF.^[@cit4]^ Notably, the presence of a double bond in **12** and **14** greatly decreased their cytotoxicities.

###### Cytotoxicities of pactamides A--F (**11--16**)

                                                  IC~50~ (μ[m]{.smallcaps})                                 
  ----------------------------------------------- --------------------------- -------------- -------------- --------------
  **11**                                          0.51 ± 0.01                 0.26 ± 0.02    0.24 ± 0.02    0.37 ± 0.03
  **12**                                          25.47 ± 1.09                24.45 ± 0.53   21.93 ± 0.58   26.15 ± 1.37
  **13**                                          2.42 ± 0.15                 0.71 ± 0.02    0.74 ± 0.02    1.71 ± 1.71
  **14**                                          19.26 ± 0.69                14.50 ± 1.56   17.41 ± 0.92   17.23 ± 1.18
  **15**                                          8.70 ± 0.25                 5.10 ± 0.43    5.19 ± 0.11    6.88 ± 0.10
  **16**                                          2.65 ± 0.29                 2.66 ± 0.04    2.85 ± 0.22    2.66 ± 0.07
  **CP** [^*a*^](#tab1fna){ref-type="table-fn"}   3.99 ± 0.49                 9.23 ± 0.41    1.53 ± 0.12    1.39 ± 0.18

^*a*^Cisplatin, positive control.

Biochemical characterization of PtmC
------------------------------------

The alcohol dehydrogenase IkaC has been previously shown to catalyse the formation of the inner five-membered ring in ikarugamycin (**7**, [Fig. 1](#fig1){ref-type="fig"}). Given the high similarity of PtmC and IkaC, we expected that PtmC should have a similar function to IkaC. To probe its function *in vitro*, PtmC was overproduced in *E. coli* BL21(DE3) as a soluble *N*-His~6~-tagged protein (Fig. S15[†](#fn1){ref-type="fn"}). *In vitro* assays showed that **13** was converted to **11** by PtmC in the presence of NADPH or NADH ([Fig. 3A](#fig3){ref-type="fig"}, traces i--iii), while no conversion of **13** to **11** was observed in the absence of PtmC or NAD(P)H ([Fig. 3A](#fig3){ref-type="fig"}, traces iv & v), or upon replacing PtmC with IkaC ([Fig. 3A](#fig3){ref-type="fig"}, trace vi). These data unequivocally established that PtmC was able to catalyse the conversion of **13** to **11**.

![Biochemical characterization of PtmC and the proposed reaction mechanism. (A) HPLC analysis of the enzyme assays. (i) **13** + PtmC + NADPH; (ii) **13** + PtmC + NADH; (iii) standard **11**; (iv) **13** + NADPH; (v) **13** + PtmC; (vi) **13** + IkaC + NADPH; (vii) **17** + NADPH; (viii) **17** + PtmC + NADPH; (ix) standard **7**. (B) The proposed mechanism of PtmC catalysis. (C) The proposed PtmC mechanism to convert **17** to **7** and **18**.](c6sc03875a-f3){#fig3}

We have previously established that the inner five-membered ring in ikarugamycin (**7**, [Fig. 1](#fig1){ref-type="fig"}) was formed through an IkaC-catalyzed 1,6-Michael addition reaction,^[@cit15]^ by deuterium incorporation experiments in coupling assays with glucose dehydrogenases (GDH), providing either (*S*)-\[4-^2^H\]NADPH by BmGDH from *Bacillus megaterium* DSM 2894,^[@cit30]^ or (*R*)-\[4-^2^H\]NADPH by TaGDH from *Thermoplasma acidophilum* ATCC 25905.^[@cit31]^

The same strategy was employed to probe the reaction mechanism of PtmC. The LC-HRESIMS analyses of the reaction product (**11**) in the PtmC/GDH coupling assays, in buffers either prepared with H~2~O or ^2^H~2~O (Fig. S16[†](#fn1){ref-type="fn"}), revealed the incorporation of two protons, one from (*R*)-\[4-H\]NADPH and another from H~2~O, into the product **11**. These observations revealed a similar 1,6-Michael addition reaction for the PtmC-catalysed formation of the six-membered ring in **11** from **13** ([Fig. 3B](#fig3){ref-type="fig"}). Similarly to IkaC catalysis, an isomerization from species **13a** to **13b** ([Fig. 3B](#fig3){ref-type="fig"}) was proposed to change *Z*Δ^2,3^ in the substrate **13** to *E*Δ^2,3^ in the product **11** during PtmC catalysis ([Fig. 3B](#fig3){ref-type="fig"}). Interestingly, PtmC could catalyse the conversion of **17** (the native substrate of IkaC^[@cit15]^) into two products ([Fig. 3A](#fig3){ref-type="fig"}, traces vii & viii), one of which was identical to **7** by comparison with authentic **7** ([Fig. 3A](#fig3){ref-type="fig"}, trace ix). Another product **18** (1.7 mg) was isolated from a preparative PtmC enzyme reaction and was structurally elucidated as isoikarugamycin by comparing its ^1^H and ^13^C NMR data (Table S8, Fig. S17[†](#fn1){ref-type="fn"}) with the reported data.^[@cit32]^ In contrast, IkaC was unable to convert **13** to **11** ([Fig. 3B](#fig3){ref-type="fig"}, trace vi), although IkaC has 65% identity with and 76% similarity to PtmC. The formation of **7** and **18** by PtmC catalysis was also consistent with a 1,6-Michael addition reaction ([Fig. 3C](#fig3){ref-type="fig"}).^[@cit32]^ These data revealed that PtmC was a bifunctional enzyme capable of catalysing the formation of both six- and five-membered rings *via* a common Michael addition mechanism.

Implications of a reductive cyclization cascade in constructing a 5/5/6 ring system in PTMs
-------------------------------------------------------------------------------------------

A substantial understanding of PTM biosynthesis has been gained for HSAF (**3**),^[@cit3],[@cit14],[@cit17],[@cit23],[@cit33]^ frontalamides (**5**, **6**),^[@cit5]^ and ikarugamycin (**7**).^[@cit1],[@cit15],[@cit16]^ The simplicity of PTM biosynthesis lies mainly in the beauty of synthesizing the polyene tetramate precursor **10** by a single PTM PKS/NRPS enzyme due to the functional iteration of PTM PKSs ([Fig. 4](#fig4){ref-type="fig"}).^[@cit1]^ This study provides further support with **10** (generated by PtmA alone, [Fig. 4](#fig4){ref-type="fig"}) as a common biosynthetic intermediate in the PTM pathway. The in-frame deletion of *ptmB2*, *ptmB1*, and *ptmC* led to the accumulation of **10**, **15**, and **13**, respectively, providing convincing evidence for a cascade of three reductive cyclization reactions to form the 5/5/6 ring system in **11** ([Fig. 4](#fig4){ref-type="fig"}). The phytoene dehydrogenase PtmB2 catalyses the first cyclization reaction, converting **10** to **15**, in a not yet understood manner. Next, the oxidoreductase PtmB1 performs the second reductive cyclization to convert **15** to **13**, probably undergoing a 1,8-Michael addition like reaction. Finally, the third reductive cyclization, mediated by the dehydrogenase PtmC, transforms **13** into **11** to furnish the 5/5/6 ring system ([Fig. 4](#fig4){ref-type="fig"}).

![Proposed biosynthetic pathway for pactamides A--F (**11--16**).](c6sc03875a-f4){#fig4}

In accordance with these hypotheses, feeding **15** into *S. lividans* TK64/pCSG2814 (where *ptmB2* is in-frame deleted and *ptmB1* and *ptmC* are intact) clearly led to the detection of compounds **13** and **11** (Fig. S18[†](#fn1){ref-type="fn"}), confirming that **15** is a biosynthetic intermediate *en route* to **11**. PtmD displays high similarity to the hydroxylases involved in the hydroxylation at C-25 of the ornithine moiety (Fig. S19[†](#fn1){ref-type="fn"}),^[@cit5],[@cit8],[@cit23],[@cit24]^ however, the absence of a C-25 hydroxy group in **11--16** suggests that PtmD might function as a C-31 hydroxylase in the biosynthesis of **12** and **14** ([Fig. 4](#fig4){ref-type="fig"}). The enzymes to generate the double bonds in **12** and **14** are still unknown, but should be encoded by genes shown in [Fig. 2A](#fig2){ref-type="fig"}, since **12** and **14** were also produced in *S. lividans*/pCSG2804 ([Fig. 2B](#fig2){ref-type="fig"}, trace v). Pactamide F (**16**) was only detected in *S. pactum* 2999PTMp1, but not in *S. lividans* TK64/pCSG2804 ([Fig. 2B](#fig2){ref-type="fig"}), indicating that the required tailoring enzymes, a halogenase and a C-11 hydroxylase, might be encoded by genes outside of the *ptm*-gene cluster.

Conclusions
===========

Six new PTMs, pactamides A--F (**11--16**), have been discovered by the successful activation of a cryptic PTM gene cluster *via* promoter engineering in marine-derived *S. pactum* SCSIO 02999. The PTM gene clusters in *S. pactum* SCSIO 02999, *S. albus* J1074 (activated by promoter engineering^[@cit18]^) and *S. griseus* IFO 13350 (activated by synthetic biology^[@cit8]^) share the same genetic organization and have high sequence similarity in their encoded proteins, however, the activation of each cluster led to structurally distinct PTMs (Fig. S20[†](#fn1){ref-type="fn"}). This indicates a great potential to discover more new bioactive PTMs by activating the hundreds of conserved and silent PTM gene clusters in phylogenetically diverse bacteria.^[@cit1],[@cit5]^ Furthermore, the discovery of the major products of the Δ*ptmB2* mutant (**10**), the Δ*ptmB1* mutant (**15**), and the Δ*ptmC* mutant (**13**), provided solid evidence for three consecutive reductive cyclizations, in a stepwise manner, to generate the 5 (in **15** by PtmB2), 5/5 (in **13** by PtmB1) and 5/5/6 (in **11** by PtmC) carbocyclic ring systems in pactamides. This discovery highlights a general strategy for the formation of a subset of 5/5/6 ring systems in other PTMs, such as in **3** and **5**. In contrast to the single enzyme IkaB-catalysed formation of the 5/6 ring system in **17**,^[@cit15]^ two oxidoreductases (PtmB2/B1) are required to generate the 5/5 ring system in **13**. This discrepancy may serve as a general predictor for divergence dictating the 5/5/6 or 5/6/5 ring systems in PTM biosynthesis, and serve to guide the genome mining approach for predicting the anticipated PTM structures. Finally, PtmC was demonstrated herein as a bifunctional cyclase to mediate the formation of both six- and five-membered rings, *via* a common Michael addition reaction mechanism .
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